Evaluating FMX-101 as a promising therapeutic for the treatment of acne

References

• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.
   PubMed Web of Science ®Google Scholar
• Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018;78(2suppl):S1–S23.
   PubMedGoogle Scholar
• Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence based review. Am J Clin Dermatol. 2017;18(4):469–490.
   PubMed Web of Science ®Google Scholar
• Gollnick HP, Bettoli V, Lambert J, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30(9):1480–1490.
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol. 2009;60:S1–S50.
   PubMed Web of Science ®Google Scholar
• Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49:S1–S37.
   PubMed Web of Science ®Google Scholar
• Goh CL, Abad-Casintahan F, Aw DC, et al. South-East Asia study alliance guidelines on the management of acne vulgaris in South-East Asian patients. J Dermatol. 2015;42(10):945–953.
   PubMed Web of Science ®Google Scholar
• Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14(6):391–399.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131(Suppl 3):S163–186.
   PubMed Web of Science ®Google Scholar
• Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1–29.
   PubMed Web of Science ®Google Scholar
• Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12.
   PubMed Web of Science ®Google Scholar
• Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474–485.
   PubMed Web of Science ®Google Scholar
• Purdy S, De Berker D. Acne vulgaris. BMJ Clin Evid. 2011;pii:1714.
   PubMedGoogle Scholar
• Scholz CF, Kilian M. The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and Pseudopropionibacterium gen. nov. Int J Syst Evol Microbiol. 2016;66(11):4422–4432.
   PubMedGoogle Scholar
• Degitz K, Placzek M, Borelli C, et al. Pathophysiology of acne. J Dtsch Dermatol Ges. 2007;5(4):316–323.
   PubMedGoogle Scholar
• Thiboutot D. Regulation of human sebaceous glands. J Invest Dermatol. 2004;123(1):1–12.
   PubMed Web of Science ®Google Scholar
• Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121(1):20–27.
   PubMed Web of Science ®Google Scholar
• Mouser PE, Baker BS, Seaton ED, et al. Propionibacterium acnes-reactive T helper-1 cells in the skin of patients with acne vulgaris. J Invest Dermatol. 2003;121(5):1226–1228.
   PubMed Web of Science ®Google Scholar
• Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258–265.
   PubMed Web of Science ®Google Scholar
• Webster G, Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25(2):133–135.
   PubMed Web of Science ®Google Scholar
• Bernier C, Dréno B. Minocycline. Ann Dermatol Venereol. 2001;128(5):627–637.
   PubMed Web of Science ®Google Scholar
• Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232–260.
   PubMed Web of Science ®Google Scholar
• Celerier P, Litoux P, Dréno B. Invitromodulation of epidermal inflammatory cytokines (IL-1 alpha, IL-6, TNF alpha) by minocycline. Arch Dermatol Res. 1996;288(7):411–414.
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12(2):12–26.
   PubMedGoogle Scholar
• Jain A, Sangal L, Basal E, et al. Anti-in- flammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J. 2002;8(2):2.
   PubMedGoogle Scholar
• Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges. 2006;4(10):828–841.
   PubMedGoogle Scholar
• Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003;(1):CD002086.
   PubMedGoogle Scholar
• Eady EA, Cove JH, Holland KT, et al. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol. 1990;122(2):233–244.
   PubMed Web of Science ®Google Scholar
• Ochsendorf F. Minocycline in acne vulgaris: benefits and risks. Am J Clin Dermatol. 2010;11(5):327–341.
   PubMed Web of Science ®Google Scholar
• Barza M, Brown RB, Shanks C, et al. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother. 1975;8(6):713–720.
   PubMed Web of Science ®Google Scholar
• Klein NC, Cunha BA. Tetracyclines. Med Clin North Am. 1995;79(4):789–801.
   PubMed Web of Science ®Google Scholar
• Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol. 1993;128(5):556–560.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis. 2004;74(2):118–122.
   PubMed Web of Science ®Google Scholar
• Noyon V, Legallou F, Richet H, et al. The resistance of Propionibacterium acnes and Staphylococcus epidermidis to cyclines. A research and study group on acne. Ann Dermatol Venereol. 1998;125(12):885–887.
   PubMed Web of Science ®Google Scholar
• Luk NMT, Hui M, Lee HCS, et al. Antibiotic-resistant Propionibacterium acnes among acne patients in a regional skin center in Hong Kong. J Eur Acad Dermatol Venereol. 2013;27(1):31–36.
   PubMed Web of Science ®Google Scholar
• RMendoza N, Hernandez PO, Tyring SK, et al. Antimicrobial susceptibility of Propionibacterium acnes isolates from acne patients in Colombia. Int J Dermatol. 2013;52(6):688–692.
   PubMed Web of Science ®Google Scholar
• Walsh TR, Efthimiou J, Dreno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect Dis. 2016;16(3):e23–33.
   PubMed Web of Science ®Google Scholar
• Biswal I, Gaind R, Kumar N, et al. In vitro antimicrobial susceptibility patterns of Propionibacterium acnes isolated from patients with acne vulgaris. J Infect Dev Ctries. 2016;10(10):1140–1145.
   PubMed Web of Science ®Google Scholar
• Harrison PV. A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin Exp Dermatol. 1988;13(4):242–244.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Kaidbey K, Gans EH. The antimicrobial effects in vivo of minocycline, doxycycline and tetracycline in humans. J Dermatol Treat. 1996;7:223–225.
   Web of Science ®Google Scholar
• Eady EA. Bacterial resistance in acne. Dermatology. 1998;196:59–66.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, McGinley KJ, Kligman AM. Tetracycline and minocycline treatments, effects on skin surface lipid levels and Propionibacterium acnes. Arch Dermatol. 1982;118:19–22.
   PubMedGoogle Scholar
• Kurokawa I, Nishijima S, Asada Y. The antibiotic susceptibility of Propionibacterium acnes: a 15-year bacteriological study and retrospective evaluation. J Dermatol. 1988;15(2):149–154.
   PubMedGoogle Scholar
• Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatologic clinics in Europe, the USA, Japan and Australia. Br J Dermatol. 2001;144(2):339–346.
   PubMed Web of Science ®Google Scholar
• Agwuh KN. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256–265.
   PubMed Web of Science ®Google Scholar
• Colaizzi JL, Klink PR. pH-partition behaviour of tetracyclines. J Pharm Sci. 1969;58(10):1184–1189.
   PubMed Web of Science ®Google Scholar
• Macdonald H, Kelly RG, Allen ES, et al. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther. 1973;14(5):852–861.
   PubMed Web of Science ®Google Scholar
• Smith K, Leyden JJ. Safety of doxycycline and minocycline: A systematic review. Clin Ther. 2005;27(9):1329–1342.
   PubMed Web of Science ®Google Scholar
• Okada N, Sato S, Sasou T, et al. Characterization of pigmented granules in minocycline-induced cutaneous pigmentation: observations using fluorescence microscopy and high-performance liquid chromatography. Br J Dermatol. 1993;129(4):403–407.
   PubMed Web of Science ®Google Scholar
• Dodiuk-Gad RP, de Morentin HM, Schafer J, et al. Minocycline-induced cutaneous hyperpigmentation: confocal laser scanning microscope analysis. J Eur Acad Dermatol Venereol. 2006;20(4):435–439.
   PubMed Web of Science ®Google Scholar
• Purdy S, DeBerker D. Acne vulgaris. BMJ Clin Evid. 2008;pii:1714.
   PubMedGoogle Scholar
• Alexis A, Del Rosso J, Desai S, et al. BPX-01 minocycline topical gel shows promise for the treatment of moderate-to-severe inflammatory acne vulgaris. J Clin Aesthet Dermatol. 2018;11(11):25–35.
   PubMedGoogle Scholar
• Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148(3):467–478.
   PubMed Web of Science ®Google Scholar
• Adler BL, Kornmehl H, Armstrong AW. Antibiotic resistance in acne treatment. JAMA Dermatol. 2017;153(8):810–811.
   PubMed Web of Science ®Google Scholar
• Grech I. Susceptibility profiles of Propionibacterium acnes isolated from patients with acne vulgaris. J Global Antimicrob Resist. 2014;2(1):35–38.
   PubMed Web of Science ®Google Scholar
• Giannopoulos L, Papaparaskevas J, Refene E, et al. MLST typing of antimicrobial-resistant Propionibacterium acnes isolates from patients with moderate to severe acne vulgaris. Anaerobe. 2015;31:50–54.
   PubMed Web of Science ®Google Scholar
• Bonati LM, Dover JS. Treating acne with topical antibiotics: current obstacles and the introduction of topical minocycline as a new treatment option. J Drugs Dermatol. 2019;18(3):240–244.
   PubMed Web of Science ®Google Scholar
• Dosik J, Ellman H, Stuart I. Topical minocycline foam 4%: results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation. J Immunotoxicol. 2019;16(1):133–139.
   PubMed Web of Science ®Google Scholar
• Minocycline compound summary. U.S. National Library of Medicine. Rockville: National Center for Biotechnology Information. [cited 2020 Jan 10]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Minocycline
   Google Scholar
• CHEBI:50694. Elixir core data resource. 2019 [cited 2020 Jan 10]. Available from: https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50694
   Google Scholar
• Jones TM, Ellman H, deVries T. Pharmacokinetic comparison of once-daily topical minocycline foam 4% vs oral minocycline for moderate-to-severe acne. J Drugs Dermatol. 2017;16(10):1022–1028.
   PubMed Web of Science ®Google Scholar
• Shemer A, Shiri J, Mashiah J, et al. Topical minocycline foam for moderate to severe acne vulgaris: phase 2 randomized double-blind, vehicle-controlled study results. J Am Acad Dermatol. 2016;74(6):1251–1252.
   PubMed Web of Science ®Google Scholar
• Minocycline. Canadian Institutes Of Health Reasearch. DrugBank; 2020 [cited 2020 Jan 10]. Available from: https://www.drugbank.ca/drugs/DB01017
   Google Scholar
• Aslam I, Fleischer A, Feldman S. Emerging drugs for the treatment of acne. Expert Opin Emerg Drugs. 2015;20(1):91–101.
   PubMed Web of Science ®Google Scholar
• Tamarkin D, Eini M, Hazot Y, et al. Compositions and methods for treating rosacea and acne. Justia patents US patent application. 2017 [cited 2020 Jan 10]. Available from: https://patents.justia.com/patent/20180064638
   Google Scholar
• Gold LS, Dhawan S, Weiss J, et al. The efficacy and safety of FMX101, minocycline foam 4%, for the treatment of acne vulgaris: A pooled analysis of phase 2 and phase 3 studies. J Am Acad Dermatol. 2019;80(1):168–177.
   PubMed Web of Science ®Google Scholar
• Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2019. S0190-9622(19)30882–5. [ Epub ahead of print].
   PubMedGoogle Scholar
• Gump DW, Ashikaga T, Fink TJ, et al. Side effects of minocycine: different dosage regimens. Antimicrob Agents Chemother. 1977;12(5):642–646.
   PubMed Web of Science ®Google Scholar
• Williams DN, Laughlin LW, Lee YH. Minocycline: possible vestibular side-effects. Lancet. 1974;2(7883):744–746.
   PubMed Web of Science ®Google Scholar
• Garrido-Mesa N, Zarzuelo A, Galvéz J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337–352.
   PubMed Web of Science ®Google Scholar
• Lawrenson R, Seaman H, Sundstrom A, et al. Liver damage associated with minocycline use in acne. A systematic review of the published literature and pharmacovigilance data. Drug Saf. 2000;23(4):333–349.
   PubMed Web of Science ®Google Scholar
• Eyuboglu M, Kalay I, Eyoboglu D. Evaluation of adolescents diagnosed with acne vulgaris for quality of life and psychosocial challenges. Indian J Dermatol. 2018;63(2):131–135.
   PubMed Web of Science ®Google Scholar
• Eroglu FO, Aktepe E, Ijlal E. The evaluation of psychiatric comorbidity, self-injurious behavior, suicide probability, and other associated psychiatric factors (loneliness, self‐esteem, life satisfaction) in adolescents with acne: A clinical pilot study. J Cosmet Dermatol. 2019;18(3):916–921.
   PubMed Web of Science ®Google Scholar
• Dunn LK, O’Neill JL, Feldman SR. Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J. 2011;17(1):1.
   PubMedGoogle Scholar
• Dreno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448–456.
   PubMed Web of Science ®Google Scholar
• Snyder S, Crandell I, Davis SA, et al. Medical adherence to acne therapy: a systematic review. Am J Clin Dermatol. 2014;15(2):87–94.
   PubMed Web of Science ®Google Scholar
• Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol. 2008 Feb;158(2):208–216.
   PubMed Web of Science ®Google Scholar
• Tamarkin D, Friedman D, Shemer A. Emollient foam in topical drug delivery. Expert Opin Drug Deliv. 2006;3(6):799–807.
   PubMedGoogle Scholar